Clarisyn · Multi-agent biomedical analysis platform · Now live

RODENT2HUMAN

The evidence exists. Knowing what to do with it is another matter. R2H builds the intelligence layer in between.

Clarisyn

Drug discovery is drowning in data and starving for clinical reasoning.

R2H builds the bridge from the first scientific question to the last abandoned compound.

How It Works

DISCOVERY

PRECLINICAL

PHASE I

PHASE II

PHASE III

Raw signals

Fragmented data

Noise

Unconnected evidence

Scattered findings

Failed drug information

R2H intelligence layer

STRUCTURED OUTPUT

[sys_init] executing multi-omics tensor alignment (v4.2.1)
> extracting pharmacokinetic embeddings ... [ok]
> noise_filter: discarding false-positive tox signals
0x8F9A2B: CROSS_SPECIES_TRANSLATION_MATRIX = [[0.82, 0.11], [0.04, 0.91]]
> mapping rodent hepatotoxicity markers to human homology
[processing] 11010100 10100010 11110011 00011010
> synthesis complete. resolving clinical outcome...
[sys] generating human-readable report...
> appending evidence trails to nodes 42-109...
> compiling toxicity prediction matrix...

Present at every question. Every stage. Every decision.

The problem. The fix.

$2.23B

Per drug.

Most of it spent on decisions that didn't have to go wrong.

10+ yrs

To market.

Every wrong question costs months. Every abandoned compound costs years.

93%

Never reach approval.

Half of those failures aren't biology they're clinical reasoning.

Most of this is preventable.

That's what R2H is built for.

Clarisyn

NeoRevive